Serratiopeptidase Use During Pregnancy

Risk Assessment and Clinical Decision-Making

• The European Society of Cardiology recommends that proven teratogens be absolutely contraindicated, and insufficient evidence medications be avoided unless maternal benefit clearly outweighs unknown fetal risk, with serratiopeptidase falling into the "insufficient evidence" category 1, 2, 3, 4, 5
• When considering serratiopeptidase for conditions like inflammation, pain, or edema, the European Heart Journal suggests identifying the specific indication requiring treatment, selecting evidence-based alternatives with established pregnancy safety profiles, and reserving unproven medications for situations where no safer alternative exists and maternal benefit is substantial 1, 2, 3, 4, 5
• The European Respiratory Journal recommends selecting well-studied safe medications as preferred options, which does not include serratiopeptidase due to the lack of human pregnancy data 3, 4, 5